Company
Glaukos
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
4
4 still marketed
Novel approvals
0
Approvals since 2021
3
Originals and new uses
Phase 3 trials
11
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Idose Tr new use Jan 27, 2026
- Epioxa Hd/Epioxa Kit approved OrphanOct 17, 2025
- Idose Tr approved Dec 13, 2023
- Photrexa Viscous In Dextran 20% approved Priority reviewOrphanJul 15, 2016
- Photrexa Viscous In Dextran 20% approved Priority reviewOrphanApr 15, 2016
- Mitosol approved Priority reviewOrphanFeb 7, 2012
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral ImplantPivotal-lookingRecruiting
Glaukos CorporationIndustry
NCT07495852 · 510 participants (planned) · Start Feb 17, 2026 · Primary completion Jun 2028
Drug: Gen 2 Travoprost Intracameral Implant; Timolol eye drops 0.5% · For: Glaucoma
Sites: Dothan, Alabama
Marketed drugs (4)
Newest FDA action first.
- Idose Tr Travoprost · 2023
- Epioxa Hd/Epioxa Kit Riboflavin 5'-Phosphate Sodium · 2025
- Photrexa Viscous In Dextran 20% Riboflavin 5'-Phosphate, Riboflavin 5'-Phosphate Sodium · 2016
- Mitosol Mitomycin · 2012
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.